Join Us

Tests to Gather More Information About ILC

Save as Favorite
Sign in to receive recommendations (Learn more)

Leer esta página en español

Additional tests will be done on the tumor tissue to gather more information about how the cancer is likely to behave and what treatments will be most effective. Examples include:

  • Grade: A pathologist examines the cancer cells under a microscope and determines how abnormal they look and behave when compared with healthy breast cells. The lower the grade, the more closely the cancer cells resemble normal cells, the more slowly they grow, and the less likely they are to spread. There are three grades of invasive lobular carcinoma: low or grade 1; moderate or grade 2; and high or grade 3.

    Grade 1 ILC cells, which are sometimes called “well-differentiated,” look and act somewhat like healthy breast cells. Grade 3 cells, also called “poorly differentiated,” are more abnormal in their behavior and appearance.
  • Surgical margins: When cancer cells are removed from the breast, the surgeon tries to take out the whole cancer with an extra area or “margin” of normal tissue around it. This is to be sure that all of the cancer is removed. The tissue around the very edge of what was removed is called the margin of resection. It is looked at very carefully to see if it is clear of cancer cells.

    The pathologist also measures the distance between the cancer cells and the outer edge of the tissue. Margins around a cancer are described in three ways:
    • Negative: No cancer cells can be seen at the outer edge. Usually, no more surgery is needed.
    • Positive: Cancer cells come right out to the edge of the tissue. More surgery may be needed.
    • Close: Cancer cells are close to the edge of the tissue, but not right at the edge. More surgery may be needed.
    What are called “negative” (or “clean”) margins can be different from hospital to hospital. In some places, doctors want at least 2 millimeters (mm) of normal tissue beyond the edge of the cancer. In other places, doctors may define a “clean margin” as less than 2 mm or more than 2 mm of healthy tissue. You may want to ask your doctor how your hospital defines clean margins.

    To help standardize the definition of negative margins, the American Society for Radiation Oncology and the Society of Surgical Oncology issued new guidelines in February 2014 saying that clear margins, no matter how small as long as there was no ink on the cancer tumor, should be the standard for lumpectomy surgery.
  • Hormone receptor assay: This tissue test determines whether or not the breast cancer has receptors for the hormones estrogen and progesterone. A positive result means that estrogen or progesterone (or both) has the ability to fuel the cancer cells’ growth. If the cancer is hormone-receptor-positive, your doctor likely will recommend hormonal therapies that block the effects of estrogen or lower estrogen levels in the body. Examples include tamoxifen and aromatase inhibitors. If you are premenopausal, your doctor may discuss other options, such as using medications to shut down your ovaries temporarily, or even surgically removing them. The ovaries are the body’s main source of estrogen before menopause.

    “Classic” or typical invasive lobular carcinoma is usually estrogen- and progesterone-receptor-positive. To learn about classic ILC, visit the Subtypes of ILC page.
  • HER2-receptor status: Another test is done to find out whether the breast cancer cells make too much of a protein called HER2 (human epidermal growth factor receptor 2). If they do, then they also have too many HER2 receptors at the cell surface. With too many receptors, breast cancer cells pick up too many growth signals and start growing too much and too fast. One way to slow down or stop the growth of the cancer cells is to block the receptors so they don't pick up as many growth signals. That’s what the medication called Herceptin (chemical name: trastuzumab) does. About 1 out of 4 breast cancers are HER2-positive, which means they can be treated with Herceptin.

    HER2-positive cancers also can be treated with Tykerb (chemical name: lapatinib), a medication that interferes with the activity of HER2 from inside the cell. Tykerb limits the amount of energy the breast cancer cells have to grow and multiply.

    Classic invasive lobular carcinoma is usually HER2-negative, however, meaning that Herceptin and Tykerb would not be used as treatments.

These tests are done on the tissue that is removed during biopsy, or, in the case of surgical margins, after the surgery to treat the cancer.

For more information about these and other tests and their results, visit Your Diagnosis.

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations

How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top